Country Industry Forecast: The Chinese Healthcare Industry

BMI View: Qatar represents a largely risk-free proposition for multinational drug manufacturers,although the potential returns are modest, on the account of a small overall market size. Additionally,despite the authorities' desire to increase the domestic medicine  |  read more...

BMI View: As a developed market, Australia represents opportunities for risk averse pharmaceuticalinvestors, given its ageing and generally affluent population. Importantly, the government is implementingcost-cutting measures to cope with escalating healthcare costs, therefore generic drugmakers  |  read more...

BMI View: We expect Namibia's negative pharmaceutical trade balance to widen as demand for medicinescontinues to be met by imports, and poor local manufacturing sees exports contract in the medium term.Headline Expenditure Forecasts Pharmaceuticals: NAD2.20bn  |  read more...

Executive Summary BMI View: Croatia's entrance into the EU will accelerate its economic liberalisation and the developmentof the country's private sector. It is also likely to bring about an influx of EU funding in modernising thecountry's  |  read more...

BMI View: Government's commitment to healthcare and growing economy will continue to be key driversthat will attract foreign pharmaceutical firms to Botswana over the long term. However, BMI maintainsthat the country needs to see significant  |  read more...